Epigral Ltd. (EPIGRAL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Epigral Ltd. (EPIGRAL) has a cash flow conversion efficiency ratio of 0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.67 Billion ≈ $28.91 Million USD) by net assets (Rs21.01 Billion ≈ $227.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Epigral Ltd. net asset quality index to measure how much of total assets are equity-financed.
Epigral Ltd. - Cash Flow Conversion Efficiency Trend (2015–2026)
This chart illustrates how Epigral Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Epigral Ltd. to evaluate the quality of earnings relative to operating cash generation.
Epigral Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epigral Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhewen Pictures Group Co Ltd
SHG:601599
|
0.048x |
|
Guangdong Shirongzhaoye Co Ltd
SHE:002016
|
0.046x |
|
Care Property Invest NV
BR:CPINV
|
0.000x |
|
Lu Thai Textile Co Ltd
SHE:000726
|
0.012x |
|
SD Biosensor Inc
KO:137310
|
0.005x |
|
Smith & Wesson Brands Inc
NASDAQ:SWBI
|
0.075x |
|
Dat Xanh Real Estate Service Contructions Corp
VN:DXG
|
0.024x |
|
Martinrea International Inc.
TO:MRE
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Epigral Ltd. (2015–2026)
The table below shows the annual cash flow conversion efficiency of Epigral Ltd. from 2015 to 2026. For the full company profile with market capitalisation and key ratios, see EPIGRAL market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs22.21 Billion ≈ $240.24 Million |
Rs3.88 Billion ≈ $41.92 Million |
0.174x | -24.57% |
| 2025-03-31 | Rs19.05 Billion ≈ $205.97 Million |
Rs4.41 Billion ≈ $47.64 Million |
0.231x | -27.04% |
| 2024-03-31 | Rs12.54 Billion ≈ $135.63 Million |
Rs3.98 Billion ≈ $43.00 Million |
0.317x | -45.86% |
| 2023-03-31 | Rs10.69 Billion ≈ $115.62 Million |
Rs6.26 Billion ≈ $67.72 Million |
0.586x | +49.81% |
| 2022-03-31 | Rs7.26 Billion ≈ $78.51 Million |
Rs2.84 Billion ≈ $30.69 Million |
0.391x | +16.69% |
| 2021-03-31 | Rs6.84 Billion ≈ $73.99 Million |
Rs2.29 Billion ≈ $24.79 Million |
0.335x | +18.71% |
| 2020-03-31 | Rs5.83 Billion ≈ $63.10 Million |
Rs1.65 Billion ≈ $17.81 Million |
0.282x | -46.78% |
| 2019-03-31 | Rs4.93 Billion ≈ $53.29 Million |
Rs2.61 Billion ≈ $28.26 Million |
0.530x | +22.00% |
| 2018-03-31 | Rs5.17 Billion ≈ $55.95 Million |
Rs2.25 Billion ≈ $24.32 Million |
0.435x | +13.58% |
| 2017-03-31 | Rs3.62 Billion ≈ $39.12 Million |
Rs1.38 Billion ≈ $14.97 Million |
0.383x | -8.46% |
| 2016-03-31 | Rs2.95 Billion ≈ $31.92 Million |
Rs1.23 Billion ≈ $13.35 Million |
0.418x | -17.91% |
| 2015-03-31 | Rs2.20 Billion ≈ $23.82 Million |
Rs1.12 Billion ≈ $12.13 Million |
0.509x | -- |
About Epigral Ltd.
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power pl… Read more